Barclays Shares Bounce After CEO Gets Positive Cancer Prognosis

Barclays PLC rose 2.6% during the afternoon session to $7.83 per share. As reported by Reuters: "LONDON, Nov 29 ( Reuters ) - The cancer affecting Barclays Chief Executive C.S. Venkatakrishnan was detected early and is "very localised", meaning doctors are optimistic, he told a conference on Tuesday. Barclays said on Monday that Venkatakrishnan would undergo 12-16 weeks of treatment in New ..." You can read more about it here. For those of you thinking about investing in the stock, here is a brief look at the company's fundamentals.

Barclays PLC, through its subsidiaries, provides various financial products and services in the United Kingdom, Europe, the Americas, Africa, the Middle East, and Asia. The company belongs to the Financial Services sector, which has an average price to earnings (P/E) ratio of 13.34 and an average price to book (P/B) ratio of 1.95. In contrast, Barclays PLC has a trailing 12 month P/E ratio of 5.4 and a P/B ratio of 0.5.

Barclays PLC has moved -22.9% over the last year compared to -13.2% for the S&P 500 -- a difference of -9.7%. Barclays PLC has a 52 week high of $12.2 and a 52 week low of $5.89.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.